Stuart Schreiber is the Morris Loeb Professor of Chemistry and Chemical Biology at Harvard University, a co-Founder of the Broad Institute, and a member of the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences.
His research integrates chemical biology and human biology to advance the science of therapeutics. He is known for his role in the development of the field of chemical biology. Key advances include the finding that small molecules can function as “molecular glues” that promote protein–protein interactions, the discovery of mTOR and its role in nutrient-response signaling, and the discovery of histone deacetylases and that chromatin marks regulate gene expression. His research has been acknowledged through awards including the Wolf Prize in Chemistry and the Arthur Cope Award. His approach to therapeutics discovery guided the development of many biotechnology companies that he founded including Vertex Pharmaceuticals and Ariad Pharmaceuticals.
Current role
Daniel G. Anderson
Founder & Scientific Advisor at Sigilon Therapeutics
Benjamin Cravatt
Founder & Scientific Advisor at Kojin Therapeutics
Stephanie Dougan
Founder & Scientific Advisor at Kojin Therapeutics
Steve Strittmatter
Founder & Scientific Advisor at ReNetx Bio
Patrick Hsu
Founder & Scientific Advisor at Spotlight Therapeutics
Dino Di Carlo
Founder & Scientific Advisor at Ferrologix